Suppr超能文献

临床实践中的晚期取栓:德国卒中登记处内 DAWN/DEFUSE3 标准的回顾性应用。

Late Thrombectomy in Clinical Practice : Retrospective Application of DAWN/DEFUSE3 Criteria within the German Stroke Registry.

机构信息

Institute of Neuroradiology, Ludwig Maximilians University (LMU) Munich, Campus Grosshadern, Marchioninistraße 15, 81377, Munich, Germany.

Department of Radiology, University Hospital, Würzburg, Germany.

出版信息

Clin Neuroradiol. 2021 Sep;31(3):799-810. doi: 10.1007/s00062-021-01033-1. Epub 2021 Jun 7.

Abstract

BACKGROUND AND PURPOSE

To provide real-world data on outcome and procedural factors of late thrombectomy patients.

METHODS

We retrospectively analyzed patients from the multicenter German Stroke Registry. The primary endpoint was clinical outcome on the modified Rankin scale (mRS) at 3 months. Trial-eligible patients and the subgroups were compared to the ineligible group. Secondary analyses included multivariate logistic regression to identify predictors of good outcome (mRS ≤ 2).

RESULTS

Of 1917 patients who underwent thrombectomy, 208 (11%) were treated within a time window ≥ 6-24 h and met the baseline trial criteria. Of these, 27 patients (13%) were eligible for DAWN and 39 (19%) for DEFUSE3 and 156 patients were not eligible for DAWN or DEFUSE3 (75%), mainly because there was no perfusion imaging (62%; n = 129). Good outcome was not significantly higher in trial-ineligible (27%) than in trial-eligible (20%) patients (p = 0.343). Patients with large trial-ineligible CT perfusion imaging (CTP) lesions had significantly more hemorrhagic complications (33%) as well as unfavorable outcomes.

CONCLUSION

In clinical practice, the high number of patients with a good clinical outcome after endovascular therapy ≥ 6-24 h as in DAWN/DEFUSE3 could not be achieved. Similar outcomes are seen in patients selected for EVT ≥ 6 h based on factors other than CTP. Patients triaged without CTP showed trends for shorter arrival to reperfusion times and higher rates of independence.

摘要

背景与目的

提供关于血管内治疗后晚期患者结局和手术相关因素的真实世界数据。

方法

我们对多中心德国卒中登记处的患者进行了回顾性分析。主要终点是 3 个月时改良 Rankin 量表(mRS)的临床结局。试验入选患者和亚组与不入选组进行了比较。二次分析包括多元逻辑回归分析,以确定良好结局(mRS≤2)的预测因素。

结果

在 1917 例接受血管内治疗的患者中,有 208 例(11%)在时间窗≥6-24 小时内进行了治疗,且符合基线试验标准。其中,27 例(13%)患者符合 DAWN 标准,39 例(19%)患者符合 DEFUSE3 标准,156 例患者不符合 DAWN 或 DEFUSE3 标准(75%),主要原因是没有灌注成像(62%;n=129)。试验不入选组(27%)的良好结局并不显著高于试验入选组(20%)(p=0.343)。具有大的试验不入选 CT 灌注成像(CTP)病变的患者有更多的出血性并发症(33%)和不良结局。

结论

在临床实践中,血管内治疗后 6-24 小时以上患者获得良好临床结局的比例与 DAWN/DEFUSE3 试验相似,无法达到。根据 CTP 以外的因素选择进行 EVT≥6 小时的患者也有类似的结局。未经 CTP 分诊的患者,到达再灌注时间更短,独立率更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验